ImmunoCellular Therapeutics (OTCBB:IMUC) provided Monday an update on its phase two clinical trial of ICT-107, its cancer vaccine for a specific type of brain tumour. The company has started the trial in 23 centres, and has received Institutional Review Board (IRB) approval from a total of 24 trial sites. The double-blind, placebo-controlled study is expected to enroll roughly 160 to 200 patients, to treat 102 subjects with specific immunological subtypes, testing the safety and efficacy of the drug in newly diagnosed patients. There are 115 patients enrolled in the study to date, ahead of the company's own schedule, it said. Enrollment for the trial is expected to be completed by the second quarter of 2012, and an interim analysis is expected when 50 percent of events (32 deaths) have been observed.